ExonHit's EHT 0202 Counters Scopolamine's Detrimental Effects on Cognition... ( PARIS March 25 /- ExonHit Therape...)

ExonHit's EHT 0202 Counters Scopolamine's Detrimental Effects on Cognition in Humans

Date:3/25/2008

PARIS, March 25 /PRNewswire-FirstCall/ -- ExonHit Therapeutics, a drug and diagnostic discovery company, announced today the results of a Phase 1 study assessing the effects of its lead compound, EHT 0202, on scopolamine-induced brain impairments in humans. ExonHit's EHT 0202 is a compound, with a novel mechanism of action, which has shown preclinical benefits on memory and neuronal loss and is currently tested in a Phase 2 clinical trial on Alzheimer disease (AD) patients.

Scopolamine interferes with the transmission of nerve impulses by acetylcholine, a substance to which it is structurally similar, thus depressing nervous system activity. Cognitive impairment due to central cholinergic dysfunction, or scopolamine administration, is measurable through electroencephalography (EEG) changes under both nonstimulus and stimulus conditions. A number of studies indicate that EEG is a sensitive measure of acetylcholine's activity and of the induced alterations elicited by scopolamine. In addition, scopolamine-induced EEG changes have been considered as possible biomarkers for AD as the impairment acetylcholine's activity is one of the landmarks of this disease.

The Phase 1, randomized, double-blind, placebo-controlled, crossover study with 3 treatments and the placebo being administered over 4 distinct periods in 12 young healthy subjects assessed the effects of single administrations of EHT 0202 (40mg, 80mg, and 120mg) on scopolamine-induced (0.6mg) cognitive impairments by using EEG recordings (spectral analysis and Event Related Potentials - ERPs) at the following time points : 1h15, 2h45 4h15, 5h45 post dose.

As expected, scopolamine significantly reduced vigilance levels and cognition as measured by spectral analysis and ERPs respectively when administered to study subjects.

The results of the spectral analysis indicate that EHT 0202 is associated with an improvement of the vigilance level at 1h15 post-dose, as shown by the signific
'/>"/>

1

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma
2. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
3. High Blood Pressure May Heighten Effects of Alzheimers Disease
4. FDA Confirms Seizure of Eyelash Product Was Not Prompted by Reports of Adverse Effects
5. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
6. Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
7. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
8. New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects
9. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
10. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
11. DNA Test Predicts Harmful Effects of Cancer Drug

Post Your Comments:

ExonHit's EHT 0202 Counters Scopolamine's Detrimental Effects on Cognition...( PARIS March 25 /- ExonHit Therape...),Health